MINZE-HEALTH
1.12.2022 15:01:43 CET | Business Wire | Press release
Minze Health announced today that White Fund, Capricorn Partners and PMV have jointly invested €3.9 million in the company to fund its further growth and product development roadmap.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005062/en/
Minze Diary, a novel and automated bladder diary enabling quicker and better treatment of LUTS. (Photo: Minze Diary)
Minze Health is a digital healthcare scale-up that enables better care for 2.3 billion people with Lower Urinary Tract Symptoms (LUTS). Most common symptoms are urinary incontinence, a weak urine stream due to an enlarged prostate, frequent voiding and night voiding. Urological complaints remain taboo subjects in today’s society, as a result of which people are often treated too late or not at all. Minze Health is committed to lowering this barrier by offering simple and accessible screening for patients and better and user-friendly diagnostic and remote monitoring tools for healthcare professionals.
White Fund, a private equity fund focused on MedTech, led the funding round and was joined by Capricorn Partners via their Capricorn Digital Growth Fund and by the Flemish investment company PMV.
Worldwide, 300 hospitals, urology practices and pelvic floor rehabilitation centers are already working with Minze’s digital health and Remote Patient Monitoring (RPM) solutions. The proceeds will be used to conduct more clinical studies in Europe and the US, to execute Minze’s product roadmap, as well as to invest in international B2B/B2C go to market strategies.
Philippe Stas, Executive Committee Member at White Fund: “We know that due to an aging population, the LUTS prevalence number will only increase. At the same time there is an enormous pressure on our healthcare system and costs are rising every year. Digital health and health at home can improve a patient's quality of life, while at the same time significantly saving on healthcare costs. We were impressed with the progress made by Minze in recent years and believe that the company plays an essential global role in the digitalization of urology healthcare.”
Katrin Geyskens, Partner at Capricorn Partners: “The combination of Minze’s hardware & software based on explainable AI makes Minze Health unique in the field of LUTS treatment. By generating unique datasets per patient, Minze enables personalized healthcare ranging from lifestyle advice to digital therapeutics. Capricorn Partners is excited to help Minze to support patients and healthcare providers in making better decisions in their daily life.”
Tine Bekaert, Senior Investment Manager at PMV: “Minze Health’s solutions to often unspoken social problems, represent enormous international potential. We are convinced that thanks to a unique combination of medical devices with low-threshold and comprehensive software diagnostics, patients around the world facing urology problems will find their way to this accessible form of home diagnostics. We therefore fully support Minze Health in this crucial phase of international expansion.”
Wilfried Woesthuis, CEO at Minze Health: “We are honored to have White Fund, Capricorn and PMV on board. Their trust in Minze helps us to achieve our mission: bring LUTS diagnostics, treatment and follow-up to the patient's home, thus making treatment more accessible. We aim to improve care for an underserved population of approx. 1.5 billion people with urinary problems, while keeping healthcare sustainable and affordable. The investment consortiums’ expertise, network and financial support will help us to realize this ultimate goal.”
For more information on White Fund, please visit www.whitefund.be
For more information on Capricorn Partners, please visit www.capricorn.be
For more information on PMV, please visit www.pmv.eu
For more information on Minze Health, please visit www.minzehealth.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corpay Cross-Border Named the Official FX Supplier of Toulouse Football Club23.4.2026 14:30:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Toulouse Football Club to become their Official Foreign Exchange (FX) Supplier. A partnership brought together by SPORTFIVE, an international sports marketing agency. Through this partnership, Corpay Cross-Border will deliver comprehensive FX risk management solutions to support Toulouse Football Club’s operations. In addition, its award-winning platform will enable the club to manage global payments seamlessly through a single point of access. “Corpay Cross-Border is proud to be named the Official FX Supplier of Toulouse Football Club,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “This partnership reinforces Corpay’s position as a leading provider of corporate payments and currency risk management solutions within prof
Philip Morris International Expands its Partnership with Ducati Corse as Decades-Long Partnership Races Forward with Purpose23.4.2026 14:00:00 CEST | Press release
ZYN branding to be present at select MotoGP races in the 2026 season and beyond Philip Morris International1 (NYSE: PM) today announced an expanded partnership with Ducati Corse for the 2026 season and beyond. This next chapter introduces a major development: the ZYN brand of nicotine pouches—the number one nicotine pouch brand globally2—will feature on Ducati Corse MotoGP liveries at select races throughout the seasons. Just as Ducati pushes the limits of performance, ZYN represents PMI’s commitment to delivering innovation, offering a product that delivers exceptional quality while being thoughtfully designed. This partnership allows ZYN to connect with adult consumers in a space they’re passionate about—and to do so in a way that’s authentic, respectful, and dynamic. Philip Morris International’s relationship with Ducati Corse began in 2003—the year Ducati arrived in MotoGP—ushering in a bold new era of ambition. Since then, the collaboration has evolved alongside both organizations
Vitrealab and poLight ASA Partner to Tackle Coherence Artifacts in Laser-LCoS AR Displays23.4.2026 14:00:00 CEST | Press release
Vitrealab GmbH and poLight ASA (OSE: PLT) today announced a collaboration to advance laser illumination architectures for LCoS-based augmented reality (AR) displays, with a focus on mitigating coherence-related image artifacts while preserving system efficiency and compactness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423345474/en/ Vitrealab GmbH and poLight ASA (OSE: PLT) today announced a collaboration to advance laser illumination architectures for LCoS-based augmented reality (AR) displays, with a focus on mitigating coherence-related image artifacts while preserving system efficiency and compactness. Vitrealab’s Quantum Light Chip combined with poLight's TWedge® wobulation technology helps create a higher performing and more manufacturable AR system. Laser-based illumination offers clear system-level advantages for LCoS based AR light engines, including high optical efficiency due to intrinsic polarization, imp
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
